<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Gonorrhea Management Algorithm - BMJ Best Practice</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css">
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: #333;
            line-height: 1.6;
            min-height: 100vh;
        }

        .container {
            display: flex;
            max-width: 1400px;
            margin: 0 auto;
            min-height: 100vh;
            position: relative;
        }

        /* Sidebar */
        .sidebar {
            position: fixed;
            left: 0;
            top: 0;
            width: 280px;
            height: 100vh;
            background: rgba(255, 255, 255, 0.95);
            backdrop-filter: blur(10px);
            padding: 2rem 1rem;
            box-shadow: 2px 0 15px rgba(0, 0, 0, 0.1);
            z-index: 1000;
            overflow-y: auto;
            transition: transform 0.3s ease;
        }

        .sidebar h2 {
            color: #2c3e50;
            margin-bottom: 1.5rem;
            font-size: 1.5rem;
            display: flex;
            align-items: center;
            gap: 0.5rem;
        }

        .progress-item {
            display: flex;
            align-items: center;
            padding: 1rem;
            margin-bottom: 0.5rem;
            border-radius: 10px;
            cursor: pointer;
            transition: all 0.3s ease;
            color: #7f8c8d;
            background: rgba(236, 240, 241, 0.5);
        }

        .progress-item:hover {
            background: rgba(52, 152, 219, 0.1);
            transform: translateX(5px);
        }

        .progress-item.active {
            background: #3498db;
            color: white;
            font-weight: 600;
        }

        .progress-item.completed {
            background: #27ae60;
            color: white;
        }

        .progress-icon {
            width: 30px;
            margin-right: 1rem;
            font-size: 1.2rem;
        }

        /* Main Content */
        .main-content {
            flex: 1;
            margin-left: 280px;
            padding: 2rem;
        }

        .header {
            text-align: center;
            color: white;
            margin-bottom: 3rem;
            padding: 2rem;
            background: rgba(0, 0, 0, 0.2);
            border-radius: 15px;
            backdrop-filter: blur(10px);
        }

        .header h1 {
            font-size: 2.5rem;
            margin-bottom: 0.5rem;
        }

        .header p {
            font-size: 1.1rem;
            opacity: 0.9;
        }

        /* Cards */
        .card {
            background: white;
            border-radius: 15px;
            margin-bottom: 2rem;
            box-shadow: 0 10px 30px rgba(0, 0, 0, 0.1);
            overflow: hidden;
            transition: transform 0.3s ease, box-shadow 0.3s ease;
        }

        .card:hover {
            transform: translateY(-5px);
            box-shadow: 0 15px 40px rgba(0, 0, 0, 0.15);
        }

        .card-header {
            padding: 1.5rem;
            display: flex;
            align-items: center;
            justify-content: space-between;
            cursor: pointer;
            transition: all 0.3s ease;
        }

        .card-header:hover {
            filter: brightness(1.1);
        }

        .card-title {
            display: flex;
            align-items: center;
            gap: 1rem;
            font-size: 1.5rem;
            font-weight: 700;
            color: white;
        }

        .card-icon {
            font-size: 2rem;
        }

        .expand-icon {
            color: white;
            font-size: 1.5rem;
            transition: transform 0.3s ease;
        }

        .card.expanded .expand-icon {
            transform: rotate(180deg);
        }

        .card-content {
            max-height: 0;
            overflow: hidden;
            transition: max-height 0.5s ease;
        }

        .card.expanded .card-content {
            max-height: 3000px;
        }

        .card-body {
            padding: 2rem;
        }

        /* Card Colors */
        .assessment-card .card-header {
            background: linear-gradient(135deg, #3498db, #2980b9);
        }

        .diagnosis-card .card-header {
            background: linear-gradient(135deg, #9b59b6, #8e44ad);
        }

        .treatment-card .card-header {
            background: linear-gradient(135deg, #27ae60, #229954);
        }

        .followup-card .card-header {
            background: linear-gradient(135deg, #e67e22, #d35400);
        }

        /* Severity Badges */
        .severity-badges {
            display: flex;
            gap: 0.5rem;
            margin-bottom: 1.5rem;
            flex-wrap: wrap;
        }

        .badge {
            padding: 0.3rem 0.8rem;
            border-radius: 20px;
            font-size: 0.8rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.5px;
            color: white;
            display: flex;
            align-items: center;
            gap: 0.3rem;
        }

        .badge-urgent {
            background: #e74c3c;
        }

        .badge-caution {
            background: #f39c12;
        }

        .badge-stable {
            background: #27ae60;
        }

        /* Content Sections */
        .content-section {
            margin-bottom: 2rem;
            padding-bottom: 1.5rem;
            border-bottom: 1px solid #ecf0f1;
        }

        .content-section:last-child {
            border-bottom: none;
            margin-bottom: 0;
        }

        .section-title {
            font-size: 1.3rem;
            font-weight: 700;
            color: #2c3e50;
            margin-bottom: 1rem;
            display: flex;
            align-items: center;
            gap: 0.5rem;
        }

        .subsection {
            margin-bottom: 1rem;
        }

        .subsection h4 {
            color: #34495e;
            margin-bottom: 0.5rem;
            font-size: 1.1rem;
        }

        .subsection p, .subsection li {
            color: #555;
            margin-bottom: 0.3rem;
        }

        .risk-factors {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 1rem;
            margin-top: 1rem;
        }

        .risk-category {
            background: #f8f9fa;
            padding: 1rem;
            border-radius: 8px;
            border-left: 4px solid #3498db;
        }

        .risk-category strong {
            color: #2c3e50;
        }

        .test-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 1rem;
            margin-top: 1rem;
        }

        .test-item {
            background: #f8f9fa;
            padding: 1rem;
            border-radius: 8px;
            border-top: 3px solid #9b59b6;
        }

        .treatment-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 1.5rem;
            margin-top: 1rem;
        }

        .treatment-protocol {
            background: #f8f9fa;
            padding: 1.5rem;
            border-radius: 10px;
            border-left: 5px solid #27ae60;
        }

        .protocol-header {
            font-weight: 700;
            color: #2c3e50;
            margin-bottom: 0.5rem;
            display: flex;
            align-items: center;
            gap: 0.5rem;
        }

        .drug-regimen {
            background: white;
            padding: 1rem;
            border-radius: 8px;
            margin-top: 0.5rem;
            border: 1px solid #e0e0e0;
        }

        .drug-name {
            font-weight: 700;
            color: #27ae60;
        }

        .followup-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(280px, 1fr));
            gap: 1.5rem;
            margin-top: 1rem;
        }

        .followup-item {
            background: #f8f9fa;
            padding: 1.5rem;
            border-radius: 10px;
            border-top: 3px solid #e67e22;
        }

        .complication-list {
            list-style: none;
            margin-top: 1rem;
        }

        .complication-list li {
            background: white;
            padding: 1rem;
            margin-bottom: 0.5rem;
            border-radius: 8px;
            border-left: 4px solid #e74c3c;
        }

        /* Responsive */
        @media (max-width: 1024px) {
            .sidebar {
                transform: translateX(-100%);
            }
            
            .sidebar.open {
                transform: translateX(0);
            }
            
            .main-content {
                margin-left: 0;
            }
            
            .mobile-menu-btn {
                display: block;
            }
        }

        .mobile-menu-btn {
            display: none;
            position: fixed;
            top: 1rem;
            left: 1rem;
            z-index: 1001;
            background: #3498db;
            color: white;
            border: none;
            padding: 0.8rem;
            border-radius: 8px;
            font-size: 1.2rem;
            cursor: pointer;
            transition: all 0.3s ease;
        }

        .mobile-menu-btn:hover {
            background: #2980b9;
        }

        /* Animations */
        @keyframes fadeInUp {
            from {
                opacity: 0;
                transform: translateY(20px);
            }
            to {
                opacity: 1;
                transform: translateY(0);
            }
        }

        .card {
            animation: fadeInUp 0.5s ease;
        }

        /* Lists */
        ul, ol {
            margin-left: 1.5rem;
            margin-bottom: 1rem;
        }

        li {
            margin-bottom: 0.5rem;
        }

        .warning-box {
            background: #fff3cd;
            border: 1px solid #ffeaa7;
            border-radius: 8px;
            padding: 1rem;
            margin: 1rem 0;
            display: flex;
            align-items: flex-start;
            gap: 0.5rem;
        }

        .warning-box i {
            color: #f39c12;
            margin-top: 0.2rem;
        }

        .info-box {
            background: #d1ecf1;
            border: 1px solid #bee5eb;
            border-radius: 8px;
            padding: 1rem;
            margin: 1rem 0;
            display: flex;
            align-items: flex-start;
            gap: 0.5rem;
        }

        .info-box i {
            color: #3498db;
            margin-top: 0.2rem;
        }

        .alert-box {
            background: #f8d7da;
            border: 1px solid #f5c6cb;
            border-radius: 8px;
            padding: 1rem;
            margin: 1rem 0;
            display: flex;
            align-items: flex-start;
            gap: 0.5rem;
        }

        .alert-box i {
            color: #e74c3c;
            margin-top: 0.2rem;
        }
    </style>
</head>
<body>
    <button class="mobile-menu-btn" onclick="toggleSidebar()">
        <i class="fas fa-bars"></i>
    </button>

    <div class="container">
        <aside class="sidebar" id="sidebar">
            <h2>
                <i class="fas fa-route"></i>
                Algorithm Progress
            </h2>
            <div class="progress-item active" onclick="scrollToSection('assessment')">
                <i class="fas fa-clipboard-check progress-icon"></i>
                <span>Assessment</span>
            </div>
            <div class="progress-item" onclick="scrollToSection('diagnosis')">
                <i class="fas fa-microscope progress-icon"></i>
                <span>Diagnosis</span>
            </div>
            <div class="progress-item" onclick="scrollToSection('treatment')">
                <i class="fas fa-syringe progress-icon"></i>
                <span>Treatment</span>
            </div>
            <div class="progress-item" onclick="scrollToSection('followup')">
                <i class="fas fa-calendar-check progress-icon"></i>
                <span>Follow-up</span>
            </div>
        </aside>

        <main class="main-content">
            <div class="header">
                <h1>Gonorrhea Management Algorithm</h1>
                <p>BMJ Best Practice Guidelines | Last updated: May 2025</p>
            </div>

            <!-- Assessment Card -->
            <div class="card assessment-card" id="assessment">
                <div class="card-header" onclick="toggleCard(this)">
                    <div class="card-title">
                        <i class="fas fa-clipboard-check card-icon"></i>
                        <span>Assessment & History</span>
                    </div>
                    <i class="fas fa-chevron-down expand-icon"></i>
                </div>
                <div class="card-content">
                    <div class="card-body">
                        <div class="severity-badges">
                            <span class="badge badge-caution"><i class="fas fa-exclamation-triangle"></i> High-Risk Groups</span>
                            <span class="badge badge-urgent"><i class="fas fa-ambulance"></i> Urgent Referral</span>
                        </div>

                        <div class="content-section">
                            <h3 class="section-title">
                                <i class="fas fa-users"></i>
                                Key Risk Factors
                            </h3>
                            <div class="risk-factors">
                                <div class="risk-category">
                                    <strong>Strong Risk Factors:</strong><br>
                                    • Age 15-24 years (4-5x higher rates)<br>
                                    • Men who have sex with men (MSM)<br>
                                    • Black ancestry (8-9x higher in US)<br>
                                    • Prior/current STI history<br>
                                    • Multiple recent partners
                                </div>
                                <div class="risk-category">
                                    <strong>Behavioral Risks:</strong><br>
                                    • Inconsistent condom use<br>
                                    • Partner's risk factors<br>
                                    • Substance use<br>
                                    • Commercial sex work<br>
                                    • History of abuse
                                </div>
                            </div>
                        </div>

                        <div class="content-section">
                            <h3 class="section-title">
                                <i class="fas fa-question-circle"></i>
                                Sexual History (5 P's)
                            </h3>
                            <div class="subsection">
                                <h4><i class="fas fa-user-friends"></i> Partners</h4>
                                <p>Sex of partners, number in prior 2 months/1 year</p>
                                
                                <h4><i class="fas fa-baby"></i> Prevention of Pregnancy</h4>
                                <p>Contraceptive use, trying to conceive</p>
                                
                                <h4><i class="fas fa-shield-alt"></i> Protection from STIs</h4>
                                <p>STI/HIV prevention methods used</p>
                                
                                <h4><i class="fas fa-bed"></i> Practices</h4>
                                <p>Oral/vaginal/anal sex, condom use</p>
                                
                                <h4><i class="fas fa-history"></i> Past STIs</h4>
                                <p>Prior STI or HIV diagnoses</p>
                            </div>
                        </div>

                        <div class="content-section">
                            <h3 class="section-title">
                                <i class="fas fa-stethoscope"></i>
                                Physical Examination
                            </h3>
                            <div class="risk-factors">
                                <div class="risk-category">
                                    <strong>Male Genital Tract:</strong><br>
                                    • Inspect penis, glans, meatus<br>
                                    • Palpate testis, epididymis, cord<br>
                                    • Prostate exam if indicated
                                </div>
                                <div class="risk-category">
                                    <strong>Female Genital Tract:</strong><br>
                                    • Inspect external genitalia<br>
                                    • Speculum exam (NO lubricant)<br>
                                    • Bimanual exam for PID<br>
                                    • Cervical motion tenderness
                                </div>
                                <div class="risk-category">
                                    <strong>Extragenital:</strong><br>
                                    • Pharyngeal exam<br>
                                    • Rectal exam<br>
                                    • Conjunctival inspection<br>
                                    • Skin lesions check
                                </div>
                            </div>
                        </div>

                        <div class="alert-box">
                            <i class="fas fa-exclamation-circle"></i>
                            <div>
                                <strong>Red Flags - Urgent Referral:</strong> Disseminated infection (DGI), meningitis, endocarditis, severe PID with surgical abdomen, tubo-ovarian abscess, neonatal sepsis
                            </div>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Diagnosis Card -->
            <div class="card diagnosis-card" id="diagnosis">
                <div class="card-header" onclick="toggleCard(this)">
                    <div class="card-title">
                        <i class="fas fa-microscope card-icon"></i>
                        <span>Diagnosis & Testing</span>
                    </div>
                    <i class="fas fa-chevron-down expand-icon"></i>
                </div>
                <div class="card-content">
                    <div class="card-body">
                        <div class="severity-badges">
                            <span class="badge badge-stable"><i class="fas fa-check-circle"></i> NAAT Preferred</span>
                            <span class="badge badge-caution"><i class="fas fa-flask"></i> Culture for Resistance</span>
                        </div>

                        <div class="content-section">
                            <h3 class="section-title">
                                <i class="fas fa-vial"></i>
                                Primary Diagnostic Tests
                            </h3>
                            <div class="test-grid">
                                <div class="test-item">
                                    <div class="protocol-header">
                                        <i class="fas fa-dna"></i>
                                        NAAT (Nucleic Acid Amplification Test)
                                    </div>
                                    <div class="drug-regimen">
                                        <strong>Preferred method</strong><br>
                                        • Urine, urethral, cervical, vaginal<br>
                                        • Self-collected or clinician-collected<br>
                                        • High sensitivity<br>
                                        • Not FDA-approved for pharynx/rectum in US
                                    </div>
                                </div>
                                <div class="test-item">
                                    <div class="protocol-header">
                                        <i class="fas fa-petri-dish"></i>
                                        Culture
                                    </div>
                                    <div class="drug-regimen">
                                        <strong>Gold standard</strong><br>
                                        • All sites including pharynx/rectum<br>
                                        • Tests antimicrobial susceptibility<br>
                                        • Lower sensitivity for pharynx (~50%)<br>
                                        • Requires viable transport
                                    </div>
                                </div>
                                <div class="test-item">
                                    <div class="protocol-header">
                                        <i class="fas fa-search"></i>
                                        Gram Stain
                                    </div>
                                    <div class="drug-regimen">
                                        <strong>Men only</strong><br>
                                        • Urethral discharge only<br>
                                        • >99% specific, >95% sensitive<br>
                                        • Intracellular gram-negative diplococci<br>
                                        • Not sufficient for women or asymptomatic
                                    </div>
                                </div>
                            </div>
                        </div>

                        <div class="content-section">
                            <h3 class="section-title">
                                <i class="fas fa-user-md"></i>
                                Testing by Patient Type
                            </h3>
                            <div class="subsection">
                                <h4><i class="fas fa-mars"></i> Men with Urethral Discharge</h4>
                                <p>Gram stain initial test → confirm with culture or NAAT</p>
                                
                                <h4><i class="fas fa-mars"></i> Men without Discharge</h4>
                                <p>First-void urine NAAT or urinalysis (leukocyte esterase)</p>
                                
                                <h4><i class="fas fa-venus"></i> Women</h4>
                                <p>NAAT of self-collected vaginal swab, urine, or endocervical swab</p>
                                
                                <h4><i class="fas fa-head-side-cough"></i> Non-Genital Sites</h4>
                                <p>Pharynx/Rectum: NAAT if available, otherwise culture</p>
                                
                                <h4><i class="fas fa-baby"></i> Infants</h4>
                                <p>Conjunctival exudates culture + antibiotic susceptibility</p>
                            </div>
                        </div>

                        <div class="content-section">
                            <h3 class="section-title">
                                <i class="fas fa-clipboard-list"></i>
                                Differential Diagnoses
                            </h3>
                            <div class="test-grid">
                                <div class="test-item">
                                    <strong>Chlamydia trachomatis</strong><br>
                                    • Most common co-infection (10x more common)<br>
                                    • Dual NAAT testing recommended
                                </div>
                                <div class="test-item">
                                    <strong>Trichomonas vaginalis</strong><br>
                                    • Wet prep low sensitivity<br>
                                    • Consider if treatment failure
                                </div>
                                <div class="test-item">
                                    <strong>Mycoplasma genitalium</strong><br>
                                    • No commercial test available<br>
                                    • Consider if persistent symptoms
                                </div>
                            </div>
                        </div>

                        <div class="info-box">
                            <i class="fas fa-info-circle"></i>
                            <div>
                                <strong>Screening Recommendations:</strong> All sexually active women <25 years annually; MSM at all exposure sites annually (q3-6 months if high risk)
                            </div>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Treatment Card -->
            <div class="card treatment-card" id="treatment">
                <div class="card-header" onclick="toggleCard(this)">
                    <div class="card-title">
                        <i class="fas fa-syringe card-icon"></i>
                        <span>Treatment Protocols</span>
                    </div>
                    <i class="fas fa-chevron-down expand-icon"></i>
                </div>
                <div class="card-content">
                    <div class="card-body">
                        <div class="severity-badges">
                            <span class="badge badge-urgent"><i class="fas fa-exclamation"></i> Monotherapy Preferred</span>
                            <span class="badge badge-caution"><i class="fas fa-pills"></i> Dual Therapy for PID</span>
                            <span class="badge badge-stable"><i class="fas fa-child"></i> Weight-Based Dosing</span>
                        </div>

                        <div class="content-section">
                            <h3 class="section-title">
                                <i class="fas fa-university"></i>
                                General Principles
                            </h3>
                            <ul>
                                <li><strong>Monotherapy:</strong> Ceftriaxone single dose (azithromycin stewardship)</li>
                                <li><strong>Chlamydia coverage:</strong> Add doxycycline 7 days if not excluded</li>
                                <li><strong>Partner treatment:</strong> Last 60 days or most recent partner</li>
                                <li><strong>Test-of-cure:</strong> 7-14 days for pharynx, 3 months for reinfection check</li>
                            </ul>
                        </div>

                        <div class="content-section">
                            <h3 class="section-title">
                                <i class="fas fa-user-injured"></i>
                                Uncomplicated Infection (≥45kg)
                            </h3>
                            <div class="treatment-grid">
                                <div class="treatment-protocol">
                                    <div class="protocol-header">
                                        <i class="fas fa-syringe"></i>
                                        Standard Regimen
                                    </div>
                                    <div class="drug-regimen">
                                        <div class="drug-name">Ceftriaxone</div>
                                        <p>500 mg IM single dose (&lt;150kg)<br>
                                        1000 mg IM single dose (≥150kg)</p>
                                    </div>
                                </div>
                                <div class="treatment-protocol">
                                    <div class="protocol-header">
                                        <i class="fas fa-pills"></i>
                                        Alternative if Unavailable
                                    </div>
                                    <div class="drug-regimen">
                                        <div class="drug-name">Cefixime</div>
                                        <p>800 mg PO single dose<br>
                                        <em>Lower efficacy for pharynx</em></p>
                                    </div>
                                </div>
                                <div class="treatment-protocol">
                                    <div class="protocol-header">
                                        <i class="fas fa-allergies"></i>
                                        Cephalosporin Allergy
                                    </div>
                                    <div class="drug-regimen">
                                        <div class="drug-name">Gentamicin + Azithromycin</div>
                                        <p>Gentamicin 240 mg IM single dose<br>
                                        Azithromycin 2 g PO single dose</p>
                                    </div>
                                </div>
                            </div>
                        </div>

                        <div class="content-section">
                            <h3 class="section-title">
                                <i class="fas fa-female"></i>
                                Complicated Infections
                            </h3>
                            <div class="treatment-grid">
                                <div class="treatment-protocol">
                                    <div class="protocol-header">
                                        <i class="fas fa-exclamation-triangle"></i>
                                        Mild-Moderate PID
                                    </div>
                                    <div class="drug-regimen">
                                        <div class="drug-name">Ceftriaxone + Doxycycline + Metronidazole</div>
                                        <p>• Ceftriaxone 500 mg IM single dose<br>
                                        • Doxycycline 100 mg PO BID x 14 days<br>
                                        • Metronidazole 500 mg PO BID x 14 days<br>
                                        <em>Outpatient treatment with 72h reassessment</em></p>
                                    </div>
                                </div>
                                <div class="treatment-protocol">
                                    <div class="protocol-header">
                                        <i class="fas fa-procedures"></i>
                                        Severe PID (Hospitalize)
                                    </div>
                                    <div class="drug-regimen">
                                        <div class="drug-name">IV Ceftriaxone + Doxycycline + Metronidazole</div>
                                        <p>• Ceftriaxone 1 g IV q24h<br>
                                        • Doxycycline 100 mg IV/PO q12h<br>
                                        • Metronidazole 500 mg IV/PO q12h<br>
                                        <em>Switch to oral after 24-48h clinical improvement</em></p>
                                    </div>
                                </div>
                                <div class="treatment-protocol">
                                    <div class="protocol-header">
                                        <i class="fas fa-eye"></i>
                                        Conjunctivitis
                                    </div>
                                    <div class="drug-regimen">
                                        <div class="drug-name">Ceftriaxone</div>
                                        <p>1 g IM single dose<br>
                                        <em>Higher dose than urogenital</em></p>
                                    </div>
                                </div>
                                <div class="treatment-protocol">
                                    <div class="protocol-header">
                                        <i class="fas fa-ambulance"></i>
                                        Disseminated Gonococcal Infection (DGI)
                                    </div>
                                    <div class="drug-regimen">
                                        <div class="drug-name">IV Ceftriaxone</div>
                                        <p>1 g IV/IM q24h<br>
                                        <em>Hospitalize + 24-48h IV → 7 days oral</em></p>
                                    </div>
                                </div>
                            </div>
                        </div>

                        <div class="content-section">
                            <h3 class="section-title">
                                <i class="fas fa-baby"></i>
                                Special Populations
                            </h3>
                            <div class="treatment-grid">
                                <div class="treatment-protocol">
                                    <div class="protocol-header">
                                        <i class="fas fa-baby"></i>
                                        Neonates (≤45kg)
                                    </div>
                                    <div class="drug-regimen">
                                        <div class="drug-name">Ceftriaxone or Cefotaxime</div>
                                        <p>• Ophthalmia: 25-50 mg/kg IV/IM x1 (max 250 mg)<br>
                                        • DGI/Bacteremia: 25-50 mg/kg IV/IM q24h x7 days<br>
                                        • Meningitis: 10-14 days treatment</p>
                                    </div>
                                </div>
                                <div class="treatment-protocol">
                                    <div class="protocol-header">
                                        <i class="fas fa-child"></i>
                                        Children ≤45kg
                                    </div>
                                    <div class="drug-regimen">
                                        <div class="drug-name">Ceftriaxone</div>
                                        <p>• Uncomplicated: 25-50 mg/kg IV/IM x1 (max 250 mg)<br>
                                        • Complicated: 50 mg/kg IV/IM q24h<br>
                                        • Consider sexual abuse evaluation</p>
                                    </div>
                                </div>
                                <div class="treatment-protocol">
                                    <div class="protocol-header">
                                        <i class="fas fa-baby-carriage"></i>
                                        Pregnant Women
                                    </div>
                                    <div class="drug-regimen">
                                        <div class="drug-name">Ceftriaxone ± Azithromycin</div>
                                        <p>• Ceftriaxone 500 mg IM single dose<br>
                                        • Azithromycin 1 g PO single dose if chlamydia not excluded<br>
                                        • Complicated: Hospitalize + specialist care</p>
                                    </div>
                                </div>
                            </div>
                        </div>

                        <div class="alert-box">
                            <i class="fas fa-exclamation-circle"></i>
                            <div>
                                <strong>Warning:</strong> Fluoroquinolones require susceptibility testing (gyrA wild-type) and have serious adverse effects. Use only when absolutely necessary and no alternatives exist.
                            </div>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Follow-up Card -->
            <div class="card followup-card" id="followup">
                <div class="card-header" onclick="toggleCard(this)">
                    <div class="card-title">
                        <i class="fas fa-calendar-check card-icon"></i>
                        <span>Follow-up & Monitoring</span>
                    </div>
                    <i class="fas fa-chevron-down expand-icon"></i>
                </div>
                <div class="card-content">
                    <div class="card-body">
                        <div class="severity-badges">
                            <span class="badge badge-stable"><i class="fas fa-check"></i> Test-of-Cure</span>
                            <span class="badge badge-caution"><i class="fas fa-redo"></i> 3-Month Rescreen</span>
                            <span class="badge badge-urgent"><i class="fas fa-exclamation"></i> Complication Watch</span>
                        </div>

                        <div class="content-section">
                            <h3 class="section-title">
                                <i class="fas fa-search"></i>
                                Test-of-Cure Protocol
                            </h3>
                            <ul>
                                <li><strong>Indicated:</strong> Non-recommended regimen used, pharyngeal infection, persistent symptoms</li>
                                <li><strong>Timing:</strong> 7-14 days post-treatment (pharynx), 2-3 weeks (NAAT clearance)</li>
                                <li><strong>Method:</strong> Culture preferred (avoid false positive NAAT)</li>
                                <li><strong>Not needed:</strong> If first-line regimen used and symptoms resolved</li>
                            </ul>
                        </div>

                        <div class="content-section">
                            <h3 class="section-title">
                                <i class="fas fa-redo"></i>
                                Rescreening Schedule
                            </h3>
                            <div class="followup-grid">
                                <div class="followup-item">
                                    <div class="protocol-header">
                                        <i class="fas fa-clock"></i>
                                        3-Month Rescreen
                                    </div>
                                    <p>All patients with gonorrhea due to high reinfection risk (7-12% within 12 months)</p>
                                </div>
                                <div class="followup-item">
                                    <div class="protocol-header">
                                        <i class="fas fa-baby"></i>
                                        Pregnant Women
                                    </div>
                                    <p>Retest in 3rd trimester if high risk persists to prevent neonatal complications</p>
                                </div>
                                <div class="followup-item">
                                    <div class="protocol-header">
                                        <i class="fas fa-users"></i>
                                        High-Risk MSM/TGW
                                    </div>
                                    <p>Screen every 3-6 months if on PEP or high-risk behaviors</p>
                                </div>
                            </div>
                        </div>

                        <div class="content-section">
                            <h3 class="section-title">
                                <i class="fas fa-exclamation-triangle"></i>
                                Complications to Monitor
                            </h3>
                            <ul class="complication-list">
                                <li>
                                    <i class="fas fa-users"></i> <strong>Pelvic Inflammatory Disease (PID):</strong> Up to 1/3 of women with gonorrhea. Leads to chronic pelvic pain (40%), tubal infertility (10.8%), ectopic pregnancy (9.1%)
                                </li>
                                <li>
                                    <i class="fas fa-male"></i> <strong>Epididymitis:</strong> <5% of men, can cause infertility or chronic inflammation
                                </li>
                                <li>
                                    <i class="fas fa-eye"></i> <strong>Ophthalmia Neonatorum:</strong> Can cause blindness if untreated. Prevent with prophylactic eye drops
                                </li>
                                <li>
                                    <i class="fas fa-syringe"></i> <strong>Disseminated Gonococcal Infection:</strong> Skin lesions, septic arthritis, meningitis, endocarditis. Hospitalization required.
                                </li>
                                <li>
                                    <i class="fas fa-hand-holding-heart"></i> <strong>Fitz-Hugh-Curtis Syndrome:</strong> Perihepatic inflammation mimicking cholecystitis
                                </li>
                            </ul>
                        </div>

                        <div class="content-section">
                            <h3 class="section-title">
                                <i class="fas fa-heart"></i>
                                Partner Management
                            </h3>
                            <ul>
                                <li>Evaluate and treat all partners from preceding 60 days</li>
                                <li>If no recent partners, treat most recent partner before 60 days</li>
                                <li>Expedited Partner Therapy (EPT) legal in some US states for heterosexual patients</li>
                                <li>Partners should abstain from sex until treatment completed (7 days) and symptoms resolved</li>
                                <li>Provide patient resources and counseling on risk reduction</li>
                            </ul>
                        </div>

                        <div class="warning-box">
                            <i class="fas fa-exclamation-triangle"></i>
                            <div>
                                <strong>Reinfection Risk:</strong> 7-12% reinfection within 12 months. Emphasize partner treatment and safe sex practices.
                            </div>
                        </div>

                        <div class="info-box">
                            <i class="fas fa-info-circle"></i>
                            <div>
                                <strong>Prognosis:</strong> Appropriate treatment resolves infection. Key morbidity is infertility, ectopic pregnancy, and chronic pelvic pain from PID. Death rare but possible from disseminated infection.
                            </div>
                        </div>
                    </div>
                </div>
            </div>

            <div style="text-align: center; margin-top: 2rem; color: white; opacity: 0.8;">
                <p><i class="fas fa-info-circle"></i> Based on BMJ Best Practice Guidelines, May 2025 | CDC STI Treatment Guidelines 2021</p>
            </div>
        </main>
    </div>

    <script>
        // Toggle card expansion
        function toggleCard(header) {
            const card = header.parentElement;
            card.classList.toggle('expanded');
            
            // Update progress indicator
            updateProgress();
        }

        // Scroll to section
        function scrollToSection(sectionId) {
            const element = document.getElementById(sectionId);
            const card = element.querySelector('.card-content');
            
            // Expand the target card
            element.classList.add('expanded');
            
            // Scroll to the card
            element.scrollIntoView({ 
                behavior: 'smooth', 
                block: 'start' 
            });
            
            // Update progress indicator
            updateProgress();
            
            // Close sidebar on mobile
            if (window.innerWidth <= 1024) {
                document.getElementById('sidebar').classList.remove('open');
            }
        }

        // Update progress indicator based on scroll position
        function updateProgress() {
            const sections = ['assessment', 'diagnosis', 'treatment', 'followup'];
            const progressItems = document.querySelectorAll('.progress-item');
            
            // Clear all active/completed states
            progressItems.forEach(item => {
                item.classList.remove('active', 'completed');
            });
            
            // Determine current section
            let currentSection = 0;
            for (let i = sections.length - 1; i >= 0; i--) {
                const section = document.getElementById(sections[i]);
                const rect = section.getBoundingClientRect();
                if (rect.top <= 200) {
                    currentSection = i;
                    break;
                }
            }
            
            // Mark items up to current as completed, current as active
            for (let i = 0; i < sections.length; i++) {
                if (i < currentSection) {
                    progressItems[i].classList.add('completed');
                } else if (i === currentSection) {
                    progressItems[i].classList.add('active');
                }
            }
            
            // Check for expanded cards and mark them as completed
            sections.forEach((sectionId, index) => {
                const card = document.getElementById(sectionId);
                if (card.classList.contains('expanded')) {
                    progressItems[index].classList.add('completed');
                }
            });
        }

        // Toggle sidebar on mobile
        function toggleSidebar() {
            const sidebar = document.getElementById('sidebar');
            sidebar.classList.toggle('open');
        }

        // Initialize on page load
        document.addEventListener('DOMContentLoaded', function() {
            // Expand first card by default
            const firstCard = document.getElementById('assessment');
            firstCard.classList.add('expanded');
            
            // Set up scroll listener
            window.addEventListener('scroll', updateProgress);
            window.addEventListener('resize', updateProgress);
            
            // Initial progress update
            updateProgress();
            
            // Add smooth scroll behavior for all internal links
            document.querySelectorAll('a[href^="#"]').forEach(anchor => {
                anchor.addEventListener('click', function (e) {
                    e.preventDefault();
                    const target = document.querySelector(this.getAttribute('href'));
                    if (target) {
                        target.scrollIntoView({
                            behavior: 'smooth',
                            block: 'start'
                        });
                    }
                });
            });
        });

        // Add keyboard navigation
        document.addEventListener('keydown', function(e) {
            if (e.key === 'Escape') {
                document.getElementById('sidebar').classList.remove('open');
            }
        });

        // Highlight badges on hover for better UX
        document.querySelectorAll('.badge').forEach(badge => {
            badge.addEventListener('mouseenter', function() {
                this.style.transform = 'scale(1.05)';
            });
            badge.addEventListener('mouseleave', function() {
                this.style.transform = 'scale(1)';
            });
        });
    </script>
</body>
</html>